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The effect of caffeine on endurance
performance after nonselective b-
adrenergic blockade
MARLEEN A. VAN BAAK and WIM H. M. SARIS
NUTRIM, Department of Human Biology, Maastricht University, Maastricht, THE NETHERLANDS
ABSTRACT
VAN BAAK, M. A. and W. H. M. SARIS. The effect of caffeine on endurance performance after nonselective b-adrenergic blockade.
Med. Sci. Sports Exerc., Vol. 32, No. 2, pp. 499–503, 2000. Purpose: This study was designed to test the hypothesis that combined
administration of propranolol and caffeine (Pr1C) would increase endurance performance compared with the administration of
propranolol alone (Pr) if caffeine would be able to increase plasma free fatty acid (FFA) availability and/or lower plasma potassium
concentration compared with propranolol administration alone. Methods: Fifteen volunteers participated in the double-blind placebo-
controlled randomized cross-over study. An endurance exercise test until exhaustion was performed after ingestion of placebo (Pl),
80-mg propranolol (Pr), and 80-mg propranolol plus 5 mgzkg21 caffeine (Pr1C). Results: Endurance time (6SD) was 79.3 6 20.4
min in the Pl trial, 22.6 6 10.8 min in the Pr trial and 31.2 6 17.2 min in the Pr1C trial (P , 0.001). The difference between the
Pr and Pr1C trials just failed to reach statistical significance (P 5 0.056). Plasma FFA concentration and plasma potassium
concentrations were similar in the Pr and Pr1C trials, but differed significantly from the Pl trial (P , 0.05). Conclusion: Although
there was a clear tendency for an improved performance in the Pr1C trial compared to the Pr trial, this improvement was not associated
with increased plasma FFA concentration and/or reduced plasma potassium concentration in the Pr1C compared to the Pr trial. These
results do not support the hypothesis that caffeine improves endurance performance by stimulating lipolysis or lowering plasma
potassium concentration. Key Words: HUMAN, EXERCISE, POTASSIUM, FREE FATTY ACIDS
b -Adrenergic receptor blocking agents are drugs thatare used very frequently for the treatment of cardio-vascular disorders, such as hypertension and isch-
emic heart disease. They inhibit the effects of sympathetic
nervous system activity that are mediated by the b-adren-
ergic receptors. During exercise the activity of the sympa-
thetic nervous system is increased in order to create the
hemodynamic and metabolic conditions necessary to pro-
vide the active muscles with the energy needed for contrac-
tion. b-Adrenergic receptor blocking agents can therefore be
expected to affect the hemodynamic and metabolic adapta-
tions during exercise. The most pronounced hemodynamic
effects of b-adrenergic blockade during exercise are a re-
duction of heart rate, cardiac output, and arterial blood
pressure (12,20). The most obvious metabolic effect is the
inhibition of lipolysis in adipocytes (1,11,20,24) and possi-
bly also in skeletal muscle (3). In addition, potassium ho-
meostasis is affected, resulting in increased plasma potas-
sium concentrations during exercise (8,20). The effects of
b-adrenergic blockade on exercise performance are quite
evident. Maximal aerobic power and maximal oxygen con-
sumption are reduced up to 20% (20). The most pronounced
effects, however, are seen during prolonged exercise. En-
durance time of prolonged exercise at work loads of 60–
80% V˙ O2max can be reduced more than 50% (20,22,23),
depending on the type and dose of b-adrenergic blocking
agent studied. This reduced performance is accompanied by
an increased subjective perception of exertion. The mecha-
nism of the reduced performance is not clear, although
inhibition of lipolysis is often considered to be important
(3,11,15,21). An alternative explanation is the effect of
b-adrenergic blockade on potassium homeostasis (20).
Caffeine is consumed regularly by many people all over
the world in the form of caffeine-containing beverages and
foods. At the dosages used by humans, caffeine probably
acts predominantly as an antagonist of the adenosine recep-
tor (13,18). In contrast to b-adrenergic blocking agents,
caffeine has been shown to increase endurance performance
(6,9,14,17,18). It also stimulates lipolysis (4,14,17), which
may be explained by its antagonistic action on the adenosine
A1 receptor in fat cells (18). An alternative or additional
explanation may be the increase in catecholamine
concentration that is induced by caffeine, which could also
stimulate lipolysis (6,7,13). There is also evidence that
caffeine stimulates sodium-potassium pump activity,
thereby lowering plasma potassium concentrations, either
by a direct effect or indirectly via increased catecholamine
levels (10,18). The mechanism of action of caffeine with
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respect to the increase in endurance performance is not fully
clear, but increased availability of free fatty acids for oxi-
dation, thus sparing glycogen, and/or the lowering of plasma
potassium levels have been suggested (4,6,10,13,18).
The present study was designed to test the following
hypotheses: 1) if the lipolytic effect of caffeine is due to
adrenaline stimulation, it should be blocked by administra-
tion of a b-adrenergic antagonist; if, on the other hand, it is
due to direct antagonism of the adipocyte adenosine recep-
tor, stimulation of lipolysis by caffeine should occur despite
b-adrenergic blockade; 2) if the effect of caffeine on plasma
potassium levels is due to adrenaline stimulation, it should
be blocked by administration of a b-adrenergic antagonist;
if, on the other hand, it is due to a direct effect on the
Na1-K1-ATPase, decreases in plasma potassium concen-
tration should occur after caffeine ingestion despite b-ad-
renergic blockade; 3) if availability of free fatty acids plays
a key role in both the impairment of endurance performance
after b-blockade and the increase in endurance performance
after caffeine ingestion, endurance performance should only
improve after simultaneous administration of a b-blocker
and caffeine compared with b-blocker administration alone
if caffeine is able to stimulate lipolysis under these condi-
tions; 4) if potassium homeostasis plays a key role in both
the impairment of endurance performance after b-blockade
and the increase in endurance performance after caffeine
ingestion, endurance performance should only increase after
simultaneous administration of a b-blocker and caffeine
compared with b-blocker administration alone if caffeine is
able to lower plasma potassium concentrations under these
conditions.
METHODS
Subjects. Fifteen young, healthy, male volunteers were
recruited for this study. They were all well-trained in en-
durance sports (runners and cyclists) and exercised at least
three times per week. Mean (6SD) age was 24.8 6 5.6 yr,
height 183.1 6 5.3 cm, body mass 72.7 6 6.1 kg, and
maximal aerobic power was 5.0 6 0.4 W/kg. The subjects
were informed about the aim of the study and its possible
risks, and all subjects gave written informed consent enter-
ing the study. The study was approved by the Ethics Com-
mittee of the University Hospital Maastricht and Maastricht
University.
Study design. The study had a double-blind placebo-
controlled randomized cross-over design. First, a progres-
sive maximal exercise test on an electromagnetically braked
cycle ergometer (Lode Excalibur, Groningen, The Nether-
lands) was performed to determine each individual’s max-
imal aerobic power (Wmax). After a 5-min warm-up period
at 100 W, work load was increased every 2.5 min by 50 W.
When heart rate was . 160 beatszmin21, the work load was
increased by 25 W per 2.5 min until exhaustion. Wmax was
defined as the highest work rate that could be maintained for
at least 1 min.
Subsequently, each subject performed three endurance
tests until exhaustion on the cycle ergometer at 70% Wmax
with at least 7 d in between each tests. All tests were
performed between 13:30 and 18:00 h. Room temperature
was kept between 19 and 21°C. Diet and exercise was
standardized on the 2 days before the endurance tests by
having the subjects complete a 2-d diet and exercise log
before the first test and asking them to keep as close as
possible to this diary on the 2 days before the other two tests.
Heavy or unusual exercise was not allowed on the day
before the tests and on the test day. In addition, subjects had
to refrain from caffeine containing products, such as coffee,
tea, chocolate, cola, etc., during the same period. On the day
of the test, no smoking was allowed. Food intake was
allowed until 2 h before the start of the test. After this, only
water intake was allowed. Two hours before the start of the
exercise test, subjects ingested two capsules containing ei-
ther placebo or propranolol (80 mg) or propranolol (80 mg)
plus caffeine (5 mgzkg21 body weight). The order of the
medications was randomized. After subjects’ arrival in the
lab, a catheter for blood sampling was inserted in a forearm
vein. The endurance test started with a 6-min warm-up
period (3 min at 30% Wmax, 3 min at 50% Wmax). There-
after, workload was increased to 70% Wmax and subjects
cycled until exhaustion. This was defined as the moment the
subjects was no longer able to maintain a pedaling rate
above 50 revolutions per minute. Strong verbal encourage-
ment was given to all subjects to cycle as long as possible.
During the test subjects were allowed to drink water ad
libitum. At regular time intervals during exercise and during
the recovery from exercise, heart rate and perceived exertion
were measured and blood was sampled from a forearm vein.
Methods
Heart rate was monitored by means of a telemetric device
(PE 3000, Polar Electro, Kempele, Finland). The Borg scale
was used to measure perceived exertion.
Blood samples were transferred to EDTA containing
1.5-mL microtest tubes and centrifuged immediately at high
speed (Eppendorf centrifuge, Hamburg, Germany). Plasma
was transferred to another microtest tube, frozen rapidly in
liquid nitrogen and stored at 250°C until further analysis.
Plasma free fatty acid concentration was determined using
the Wako C test kit (Wako Chemicals, Neuss, Germany) on
a Cobas-Fara centrifugal spectrophotometer (Roche, Basel,
Switzerland). Plasma potassium concentration was deter-
mined by flame photometry (model 243, Instrumentation
Laboratory, Lexington, MA). In all analyses, plasma sam-
ples with known concentrations were included for quality
control.
Data analysis. All data are presented as mean 6 SD.
Differences among the three trials were analyzed with re-
peated measurements ANOVA. The difference between the
propranolol (Pr) trial and the propranolol plus caffeine
(Pr1C) trial was analyzed by means of paired Student’s
t-tests. P , 0.05 was regarded as statistically significant.
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RESULTS
Heart rate was significantly (P , 0.001) reduced in all
subjects during the propranolol (Pr) and the propranolol plus
caffeine (Pr1C) trials as compared with the placebo (Pl)
trial (Fig. 1). No difference in heart rate was found between
the Pr and Pr1C trials. At 10 min, exercise heart rate was
160.8 6 9.6 beatszmin21 min during Pl, 128.9 6 15.3
beatszmin21 during Pr and 129.2 6 11.1 beatszmin21 during
Pr1C.
The mean endurance time in all 15 subjects was 79.3 6
20.4 min in the placebo (Pl) trial, 22.6 6 10.8 min in the
propranolol (Pr) trial, and 31.2 6 17.2 min in the propran-
olol plus caffeine (Pr1C) trial (P , 0.001). During the Pl
trial, endurance times ranged from 51 to 105 min. During
the Pr and Pr1C trials, endurance time was reduced in all
subjects in comparison with the Pl trial. The difference in
endurance time between the Pr and the Pr1C trials just
failed to reach statistical significance (P 5 0.056): 11 of the
15 subjects improved their performance in the Pr1C trial in
comparison with the Pr trial, in two it was almost un-
changed, and in three it was reduced further.
The rating of perceived exertion at 10 min exercise was
11.4 6 2.1 in the Pl trial, 15.7 6 2.0 in the Pr trial, and
13.9 6 2.7 in the Pr1C trial (P , 0.001). The difference
between the Pr and the Pr1C trial was statistically signifi-
cant (P 5 0.05).
During and after exercise, plasma free fatty acid concen-
tration was significantly lower during the Pr and Pr1C trials
than during the Pl trial (P , 0.05) (Fig. 2). The difference
between the Pr and Pr1C trials was not statistically signif-
icant. During exercise the plasma potassium concentration
was significantly higher in the Pr and Pr1C trials than in the
Pl trial (P , 0.001), but the difference rapidly disappeared
during recovery (Fig. 3). There was no difference in potas-
sium concentration between the Pr and the Pr1C trial.
DISCUSSION
At the start of the study we hypothesized that combined
administration of caffeine and propranolol (Pr1C) would
increase endurance performance compared with the admin-
istration of propranolol alone (Pr) if caffeine would be able
to increase plasma free fatty acid availability and/or lower
plasma potassium concentration compared with propranolol
administration alone. Despite the fact that addition of caf-
feine did not change the plasma free fatty acid or potassium
concentrations during endurance exercise compared with
propranolol ingestion alone, there was a clear tendency for
an improvement of endurance performance in the Pr1C trial
compared with the Pr trial. This suggests that the ergogenic
effect of caffeine during endurance exercise is not related to
its effects on lipolysis or potassium homeostasis during
prolonged exercise. Moreover, the increase in FFA concen-
tration (4,14,17) and decrease in potassium concentration
(10) during exercise that have been found after caffeine
ingestion appear to be due to increased catecholaminergic
stimulation of lipolysis and Na1-K1-ATPase activity, be-
cause both effects were completely prevented by simulta-
neous propranolol administration.
b-Adrenergic receptor blocking agents are known to im-
pair endurance exercise performance quite dramatically.
This is especially true for the nonselective b-blocking
agents that block both b1- and b2-adrenergic receptors,
where reductions of endurance time up to 54% have been
found (20,22). A pronounced reduction of endurance time in
the trials where propranolol, a nonselective b-blocker, was
given was therefore to be expected in this study. The
Figure 1—Heart rate (mean 6 SD) during the placebo (squares),
propranolol (circles), and propranolol1caffeine (triangles) trials (N 5
15). E 5 moment of exhaustion, E15 and E115 5 5 and 15 min
recovery; respectively.
Figure 2—Plasma free fatty acid concentration (mean 6 SD) during
the placebo (squares), propranolol (circles), and propranolol1caffeine
(triangles) trials (N 5 15). E 5 moment of exhaustion, E15 and
E115 5 5 and 15 min recovery, respectively.
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magnitude of the impairment (70 6 15% in the Pr trial),
however, was larger than in our previous studies with the
same dose of propranolol (80 mg) and the same exercise test
(40% (21), 51% (22), and 54% (23)). The heart rate reduc-
tion after propranolol ingestion, which is due to blockade of
the cardiac b-adrenergic receptors, was slightly smaller in
this (Dheart rate 32 beatszmin21) than in previous studies
(Dheart rate 41, 43, and 43 beatszmin21 (21–23)), indicating
that the more pronounced impairment of endurance perfor-
mance in this study can not be explained by a higher level
of b-blockade. We can only speculate about the reason for
this difference, but maybe the better training status of the
subjects in this study plays a role. As in previous studies
with nonselective b-blocker administration, plasma free
fatty acid concentrations during and especially after exercise
were significantly reduced, indicating inhibition of b1- and
b2-adrenergic receptor mediated adipose tissue lipolysis
(1,20,24). Plasma potassium concentrations were increased
during exercise after b-blockade, which is probably due to
inhibition of the b2-adrenergic receptor stimulated sodium-
potassium pump (2,8,20).
The mechanism of the pronounced reduction in endur-
ance performance during b-blockade has, surprisingly in
view of the magnitude of the effect, not yet been elucidated.
One of the hypotheses is that b-blockade reduces the avail-
ability of free fatty acids for oxidation by inhibition of
lipolysis. As a consequence, oxidation of carbohydrates
increases and glycogen is depleted more rapidly, thus im-
pairing endurance performance. In support of this hypoth-
esis are the reduced plasma free fatty acid concentrations,
the reduced breakdown of intramuscular triglycerides (3),
and the often increased respiratory exchange ratio (20), but
other findings do not support this assumption. For instance,
muscle glycogen depletion does not seem to be more rapid,
and skeletal muscle free fatty acid uptake is not severely
impaired during exercise after b-blocker ingestion
(3,5,15,23). The other hypothesis is that the disturbance of
potassium homeostasis after b-blocker ingestion is respon-
sible for the impaired performance. By altering the activity
of the sodium-potassium pump, b-blockade may effect
changes in plasma [K1] and muscle excitability, which may
be associated with fatigue (16,19).
To shed some more light on this discussion we designed
the present study in which we combined the administration
of propranolol with the ingestion of caffeine. Caffeine has
been shown to increase endurance exercise performance, to
increase lipolysis, and to decrease plasma potassium con-
centrations. Caffeine thus has exactly the opposite effects on
these parameters as propranolol. This is not unexpected
because the mechanisms of action of caffeine, adenosine
antagonism in peripheral tissues, and increased catechol-
amine, especially epinephrine, production lead to an in-
crease in cAMP production, whereas b-blockade reduces
cAMP production. Before the start of the study, we hypoth-
esized that combined administration of caffeine and pro-
pranolol would lead to an improvement of endurance per-
formance compared with propranolol alone, if caffeine
would be able to stimulate lipolysis under conditions of
b-blockade. If the stimulation of lipolysis by caffeine was
predominantly due to the increase in epinephrine levels after
caffeine, this increase would be prevented by simultaneous
b-blocker administration. On the other hand, if the increased
lipolysis and/or reduced plasma [K1] were due to adenosine
antagonism, they might still be present in the presence of
blockade of the b-receptors by propranolol. In our study, we
found no difference in the plasma free fatty acid or potas-
sium concentrations during the Pr and the Pr1C trials. This
suggests that the effects of caffeine on lipolysis and potas-
sium homeostasis are predominantly due to the caffeine-
mediated increase in catecholamine concentrations and are
thus inhibited by simultaneous propranolol ingestion. As
indicated above, if a reduced availability of free fatty acids
and/or increased plasma potassium concentrations are cen-
tral in the performance reducing effect of b-blockade, we
expected to find no increase in endurance performance due
to the addition of caffeine because caffeine did not affect
plasma free fatty acids or potassium concentrations under
these conditions. In contrast, we did see a very strong
tendency, just not statistically significant (P 5 0.06), for an
improvement of endurance performance by caffeine. An
enhancing effect of caffeine on performance during
b-blockade was supported by the lower perceived exertion
during the Pr1C trial compared with the Pr trial, which is in
our hands is the best predictor of endurance performance of
all variables measured in this type of test (unpublished
observations). These results do not support the hypothesis
that caffeine improves endurance performance by stimulat-
ing lipolysis, thus increasing the free fatty acid availability
for energy production and thereby delaying glycogen deple-
tion and fatigue. Neither can changes in plasma potassium
Figure 3—Plasma potassium concentration (mean 6 SD) during the
placebo (squares), propranolol (circles), and propranolol1caffeine (tri-
angles) trials (N 5 15). E 5 moment of exhaustion, E15 and E115 5
5 and 15 min recovery, respectively.
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concentration explain the effect of caffeine on performance.
Graham and Spriet (7) in their study also provided evidence
that the performance enhancing effect of caffeine was un-
related to its catecholamine-stimulating effect.
In conclusion, although it is evident that propranolol and
caffeine both have pronounced and opposite metabolic ef-
fects, these metabolic effects do not appear to be able to
explain the pronounced and opposite effects of propranolol
and caffeine on endurance performance.
The authors wish to thank Kim Peters and Jean Herpers for their
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